You are in:Home/Publications/Assessment of eight non-invasive markers of liver fibrosis in Egyptian patients with chronic hepatitis C.

Prof. mohamed magdy elsadek atta :: Publications:

Title:
Assessment of eight non-invasive markers of liver fibrosis in Egyptian patients with chronic hepatitis C.
Authors: Mohamed Magdi E. Atta, Entesar H. El Sharkawy, Ebada Said, Hala M. El Feky, Naglaa El Toukhy
Year: 2011
Keywords: Not Available
Journal: Journal of Gastroenterology
Volume: 140
Issue: 5
Pages: s-457
Publisher: Not Available
Local/International: Local
Paper Link: Not Available
Full paper mohamed magdy elsadek atta_Assessment of eight non-invasive markers of liver fibrosis in Egyptian patients with chronic hepatitis C. .pdf
Supplementary materials Not Available
Abstract:

Background/Aim: Many non-invasive alternatives to liver biopsy for assessment of hepatic fibrosis are proposed, yet their accuracy and applicability remain questionable. This study assesses the diagnostic and predictive values of 8 simple, inexpensive serum markers of liver fibrosis in Egyptian patients with chronic hepatitis C virus (HCV) infection. Subjects & Methods: Complete blood count (CBC), alanine aminotransferase(ALT), aspartate aminotransferase( AST), serum bilirubin, serum albumin, prothrombin time (PT), international normalized ratio (INR) and liver biopsy were examined for 142 patients with chronic HCV infection. Fibrosis (F) was staged using METAVIR scoring system (F0-F4). AST/ALT ratio (AAR), Age-platelets index (API), AST-platelets ratio index (APRI), cirrhosis discriminate score (CDS), King, FIB-4, Lok's {Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C)} model, and Pohl scores were calculated using published formulas. Area under receiver operating characteristic curves (AUROC) was applied to determine the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of each assessed marker. Results: Among the assessed scores, FIB-4 and King scores were superior to others for prediction of significant fibrosis (F2-F3) and cirrhosis (F4). The diagnostic performance of FIB-4 was 59% (AUROC 0.59) with 80% sensitivity, 41% specificity, 94% PPV, 65.2% NPV, at cutoff 0.98 while that of King score was 57% (AUROC 0.57) with 80% sensitivity, 40% specificity, 86.4% PPV, 60% NPV at cutoff 8.2. When the 2 markers were combined, the overall accuracy was 80.7% with 87.5% sensitivity, 64.7% specificity, 85.36% PPV, 68.75% NPV in patients with F2 -F3. For predicting cirrhosis (F4), the diagnostic performance of FIB-4 was 81% (AUROC 0.81) with 90% sensitivity, 65% specificity, 93.75% PPV, 88.2% NPV at cut-off 1.3, and that of King score was 79% (AUROC 0.79) with 90% sensitivity, 53% specificity, 96.7% PPV, 84.8% NPV at cut-off 9.8. When the 2 markers are combined the overall accuracy was 89.79% with 93.75% sensitivity, 82.35% specificity, 90.9% PPV, 87.5% NPV. Conclusion: FIB-4 and King scores were the most accurate among different non-invasive fibrosis markers in Egyptian patients with chronic HCV and their accuracy improves when they are combined.

Google ScholarAcdemia.eduResearch GateLinkedinFacebookTwitterGoogle PlusYoutubeWordpressInstagramMendeleyZoteroEvernoteORCIDScopus